Elizabeta Nemeth

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4060435/publications.pdf

Version: 2024-02-01

200 papers	30,326 citations	84 h-index	170 g-index
		5782	5347
208 all docs	208 docs citations	208 times ranked	17465 citing authors

#	Article	IF	Citations
1	Erythroid overproduction of erythroferrone causes iron overload and developmental abnormalities in mice. Blood, 2022, 139, 439-451.	0.6	18
2	Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin. Kidney International, 2022, 101, 711-719.	2.6	8
3	Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib. British Journal of Haematology, 2022, 197, .	1.2	8
4	Human defensin-inspired discovery of peptidomimetic antibiotics. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117283119.	3.3	16
5	Hepcidin and Erythroferrone Complement the Athlete Biological Passport in the Detection of Autologous Blood Transfusion. Medicine and Science in Sports and Exercise, 2022, 54, 1604-1616.	0.2	13
6	Integrated regulation of stress responses, autophagy and survival by altered intracellular iron stores. Redox Biology, 2022, 55, 102407.	3.9	19
7	Isolation and thermal stabilization of mouse ferroportin. FEBS Open Bio, 2021, 11, 26-34.	1.0	1
8	Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. Annals of Medicine, 2021, 53, 274-285.	1.5	28
9	Pursuing Orally Bioavailable Hepcidin Analogues via Cyclic N-Methylated Mini-Hepcidins. Biomedicines, 2021, 9, 164.	1.4	4
10	INTERGROWTH-21 Identifies High Prevalence of Low Symphysisâ€“Fundal Height in Indigenous Pregnant Women Experiencing Multiple Infections, Nutrient Deficiencies, and Inflammation: The Maternal Infections, Nutrient Deficiencies, and Inflammation (MINDI) Cohort. Current Developments in Nutrition, 2021, 5, nzab012.	0.1	6
11	Serum Erythroferrone During Pregnancy Is Related to Erythropoietin but Does Not Predict the Risk of Anemia. Journal of Nutrition, 2021, 151, 1824-1833.	1.3	12
12	Detection of a Smallâ€Volume Autologous Blood Transfusion by Hepcidin, Erythroferrone, and the Athlete Biological Passport. FASEB Journal, 2021, 35, .	0.2	0
13	The hepcidin regulator erythroferrone is a new member of the erythropoiesis-iron-bone circuitry. ELife, 2021, 10, .	2.8	18
14	Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2021, 321, R152-R161.	0.9	9
15	Prepregnancy Obesity Does Not Impact Placental Iron Trafficking. Journal of Nutrition, 2021, 151, 2646-2654.	1.3	6
16	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	2.6	103
17	Iron-dependent apoptosis causes embryotoxicity in inflamed and obese pregnancy. Nature Communications, 2021, 12, 4026.	5.8	12
18	Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis. International Journal of Molecular Sciences, 2021, 22, 6493.	1.8	205

#	Article	IF	Citations
19	Umbilical Cord Erythroferrone Is Inversely Associated with Hepcidin, but Does Not Capture the Most Variability in Iron Status of Neonates Born to Teens Carrying Singletons and Women Carrying Multiples. Journal of Nutrition, 2021, 151, 2590-2600.	1.3	12
20	Iron deficiency and blood cadmium concentrations in a cohort of reproductive-age women. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
21	Vaccine efficacy and iron deficiency: an intertwined pair?. Lancet Haematology,the, 2021, 8, e666-e669.	2.2	28
22	Iron loading induces cholesterol synthesis and sensitizes endothelial cells to TNFÎ±-mediated apoptosis. Journal of Biological Chemistry, 2021, 297, 101156.	1.6	14
23	Erythroferrone Modulates Iron Distribution for Fetal Erythropoiesis. Blood, 2021, 138, 757-757.	0.6	0
24	Iron overload causes a mild and transient increase in acute lung injury. Physiological Reports, 2020, 8, e14470.	0.7	6
25	Lung Iron Overload Does Not Exacerbate the Fibrotic Response to Bleomycin in a Mouse Model of Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 713-716.	1.4	1
26	Prognostic associations of plasma hepcidin in women with early breast cancer. Breast Cancer Research and Treatment, 2020, 184, 927-935.	1.1	5
27	Maternal hepcidin determines embryo iron homeostasis in mice. Blood, 2020, 136, 2206-2216.	0.6	37
28	Regulation of iron homeostasis through the erythroferroneâ€hepcidin axis in sickle cell disease. British Journal of Haematology, 2020, 189, 1204-1209.	1.2	13
29	Clinical Immunoassay for Human Hepcidin Predicts Iron Deficiency in First-Time Blood Donors. journal of applied laboratory medicine, The, 2020, 5, 943-953.	0.6	7
30	Fetal and amniotic fluid iron homeostasis in healthy and complicated murine, macaque, and human pregnancy. JCI Insight, 2020, 5, .	2.3	24
31	Maternal Hepcidin Suppression Is Essential for Healthy Pregnancy. Blood, 2020, 136, 43-44.	0.6	2
32	Transgenic Mice Overexpressing Erythroferrone, a Novel Erythrokine, Develop Iron Overload and Multi-Organ Iron-Independent Abnormalities. Blood, 2020, 136, 12-12.	0.6	1
33	Iron-Dependent Apoptosis Causes Embryotoxicity in Inflamed and Obese Pregnancy. Blood, 2020, 136, 12-12.	0.6	0
34	Placental iron transport: The mechanism and regulatory circuits. Free Radical Biology and Medicine, 2019, 133, 254-261.	1.3	67
35	Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrology Dialysis Transplantation, 2019, 34, 2057-2065.	0.4	73
36	A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome. Science Translational Medicine, 2019, 11, .	5.8	55

#	Article	IF	Citations
37	To induce or not to induce: the fight over hepcidin regulation. Haematologica, 2019, 104, 1093-1095.	1.7	9
38	Increased gene copy number of DEFA1/DEFA3 worsens sepsis by inducing endothelial pyroptosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3161-3170.	3.3	41
39	Umbilical Cord Serum Ferritin Concentration is Inversely Associated with Umbilical Cord Hemoglobin in Neonates Born to Adolescents Carrying Singletons and Women Carrying Multiples. Journal of Nutrition, 2019, 149, 406-415.	1.3	17
40	Iron in Lung Pathology. Pharmaceuticals, 2019, 12, 30.	1.7	32
41	Single versus Split Dose of Iron Optimizes Hemoglobin Mass Gains at 2106 m Altitude. Medicine and Science in Sports and Exercise, 2019, 51, 751-759.	0.2	25
42	Iron homeostasis in pregnancy and spontaneous abortion. American Journal of Hematology, 2019, 94, 184-188.	2.0	33
43	Effects of maternal iron status on placental and fetal iron homeostasis. Journal of Clinical Investigation, 2019, 130, 625-640.	3.9	119
44	The Aftermath of Surviving Acute Radiation Hematopoietic Syndrome and its Mitigation. Radiation Research, 2019, 191, 323.	0.7	17
45	Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica, 2018, 103, e141-e142.	1.7	38
46	Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. Hepatology International, 2018, 12, 83-86.	1.9	41
47	Intravenous Iron Does Not Augment the Hemoglobin Mass Response to Simulated Hypoxia. Medicine and Science in Sports and Exercise, 2018, 50, 1669-1678.	0.2	32
48	Fetal presentation of congenital dyserythropoietic anemia type 1 with novel compound heterozygous CDAN1 mutations. Blood Cells, Molecules, and Diseases, 2018, 71, 63-66.	0.6	8
49	Hepcidin agonists as therapeutic tools. Blood, 2018, 131, 1790-1794.	0.6	91
50	Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood, 2018, 131, 899-910.	0.6	230
51	Erythroferrone is not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment in mice. Physiological Reports, 2018, 6, e13890.	0.7	23
52	Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E1185-E1193.	1.8	24
53	Hepcidin Protects against Lethal Escherichia coli Sepsis in Mice Inoculated with Isolates from Septic Patients. Infection and Immunity, 2018, 86, .	1.0	46
54	Calcium is an essential cofactor for metal efflux by the ferroportin transporter family. Nature Communications, 2018, 9, 3075.	5.8	47

#	Article	IF	Citations
55	Hepatic hepcidin/intestinal HIF-2Î± axis maintains iron absorption during iron deficiency and overload. Journal of Clinical Investigation, 2018, 129, 336-348.	3.9	138
56	Regulation of the Iron Homeostatic Hormone Hepcidin. Advances in Nutrition, 2017, 8, 126-136.	2.9	289
57	Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model. Haematologica, 2017, 102, e85-e88.	1.7	17
58	Erythroferrone and matriptaseâ€2 independently regulate hepcidin expression. American Journal of Hematology, 2017, 92, E61-E63.	2.0	25
59	Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing nonâ€“transferrin-bound iron. Blood, 2017, 130, 245-257.	0.6	105
60	In a Mouse Model of Sepsis, Hepcidin Ablation Ameliorates Anemia More Effectively than Iron and Erythropoietin Treatment. Shock, 2017, 48, 490-497.	1.0	17
61	Iron homeostasis during pregnancy. American Journal of Clinical Nutrition, 2017, 106, 1567S-1574S.	2.2	213
62	Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica, 2017, 102, e427-e430.	1.7	93
63	Hamp1 mRNA and plasma hepcidin levels are influenced by sex and strain but do not predict tissue iron levels in inbred mice. American Journal of Physiology - Renal Physiology, 2017, 313, G511-G523.	1.6	8
64	Iron Metabolism in African American Women in the Second and Third Trimesters of High-Risk Pregnancies. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2017, 46, 148-158.	0.2	5
65	Immunoassay for human serum erythroferrone. Blood, 2017, 130, 1243-1246.	0.6	104
66	Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia. JCI Insight, 2017, 2, e92002.	2.3	67
67	Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. American Journal of Physiology - Renal Physiology, 2016, 311, F1369-F1377.	1.3	54
68	Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Seminars in Nephrology, 2016, 36, 87-93.	0.6	124
69	Hepcidin in the diagnosis of iron disorders. Blood, 2016, 127, 2809-2813.	0.6	309
70	Minihepcidin peptides as disease modifiers in mice affected by Î²-thalassemia and polycythemia vera. Blood, 2016, 128, 265-276.	0.6	123
71	Isocitrate treatment of acute anemia of inflammation in a mouse model. Blood Cells, Molecules, and Diseases, 2016, 56, 31-36.	0.6	10
72	Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of Î²-thalassemia. Blood, 2015, 126, 2031-2037.	0.6	245

#	Article	IF	Citations
73	New insights into iron regulation and erythropoiesis. Current Opinion in Hematology, 2015, 22, 199-205.	1.2	142
74	Thiol-derivatized minihepcidins retain biological activity. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 763-766.	1.0	26
75	Hepcidin-Induced Hypoferremia Is a Critical Host Defense Mechanism against the Siderophilic Bacterium Vibrio vulnificus. Cell Host and Microbe, 2015, 17, 47-57.	5.1	194
76	A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis. Haematologica, 2015, 100, 167-177.	1.7	28
77	Iron homeostasis in host defence and inflammation. Nature Reviews Immunology, 2015, 15, 500-510.	10.6	593
78	Evidence that the expression of transferrin receptor 1 on erythroid marrow cells mediates hepcidin suppression in the liver. Experimental Hematology, 2015, 43, 469-478.e6.	0.2	25
79	Small cyclic agonists of iron regulatory hormone hepcidin. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4961-4969.	1.0	35
80	Hepcidin and iron disorders: new biology and clinical approaches. International Journal of Laboratory Hematology, 2015, 37, 92-98.	0.7	58
81	Ironing out Ferroportin. Cell Metabolism, 2015, 22, 777-787.	7.2	474
82	Hepcidin and Host Defense against Infectious Diseases. PLoS Pathogens, 2015, 11, e1004998.	2.1	163
83	Ferroportinâ€mediated cellular iron efflux requires extracellular calcium. FASEB Journal, 2015, 29, 566.15.	0.2	0
84	Mouse Models of Anemia of Cancer. PLoS ONE, 2014, 9, e93283.	1.1	21
85	Hepcidin and Iron Homeostasis during Pregnancy. Nutrients, 2014, 6, 3062-3083.	1.7	129
86	Total Synthesis of Human Hepcidin through Regioselective Disulfideâ€Bond Formation by using the Safetyâ€Catch Cysteine Protecting Group 4,4â€²â€Dimethylsulfinylbenzhydryl. Angewandte Chemie - International Edition, 2014, 53, 2931-2934.	7.2	46
87	The pathophysiology and pharmacology of hepcidin. Trends in Pharmacological Sciences, 2014, 35, 155-161.	4.0	122
88	Functional properties of human ferroportin, a cellular iron exporter reactive also with cobalt and zinc. American Journal of Physiology - Cell Physiology, 2014, 306, C450-C459.	2.1	101
89	A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood, 2014, 123, 1129-1136.	0.6	119
90	Disordered hepcidinâ€“ferroportin signaling promotes breast cancer growth. Cellular Signalling, 2014, 26, 2539-2550.	1.7	108

#	Article	IF	Citations
91	Systemic and tumor level iron regulation in men with colorectal cancer: a case control study. Nutrition and Metabolism, 2014, 11, 21.	1.3	14
92	Hepcidin Induction by Pathogens and Pathogen-Derived Molecules Is Strongly Dependent on Interleukin-6. Infection and Immunity, 2014, 82, 745-752.	1.0	99
93	Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature Genetics, 2014, 46, 678-684.	9.4	890
94	Anemia of Inflammation. Hematology/Oncology Clinics of North America, 2014, 28, 671-681.	0.9	321
95	Erythroferrone contributes to recovery from anemia of inflammation. Blood, 2014, 124, 2569-2574.	0.6	132
96	Molecular liaisons between erythropoiesis and iron metabolism. Blood, 2014, 124, 479-482.	0.6	111
97	Use of Minihepcidins As a â€œMedical Phlebotomyâ€•in the Treatment of Polycythemia Vera. Blood, 2014, 124, 3231-3231.	0.6	1
98	Concurrent Treatment with Minhepcidin and Deferiprone Improves Anemia and Enhances Reduction of Spleen Iron in a Mouse Model of Non-Transfusion Dependent Thalassemia. Blood, 2014, 124, 748-748.	0.6	6
99	Testing the Iron Hypothesis in a Mouse Model of Atherosclerosis. Cell Reports, 2013, 5, 1436-1442.	2.9	44
100	Design, synthesis, and characterization of cyclic analogues of the iron regulatory peptide hormone hepcidin. Biopolymers, 2013, 100, 519-526.	1.2	12
101	High-Throughput Screening of Small Molecules Identifies Hepcidin Antagonists. Molecular Pharmacology, 2013, 83, 681-690.	1.0	67
102	Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. Journal of Crohn's and Colitis, 2013, 7, e286-e291.	0.6	54
103	Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell, 2013, 12, 280-291.	3.0	147
104	Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica, 2013, 98, 1667-1676.	1.7	101
105	Hepcidin and Î²-thalassemia major. Blood, 2013, 122, 3-4.	0.6	30
106	Anti-hepcidin therapy for iron-restricted anemias. Blood, 2013, 122, 2929-2931.	0.6	20
107	Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy. Haematologica, 2013, 98, 1324-1330.	1.7	21
108	The Erythroid Factor Erythroferrone and Its Role In Iron Homeostasis. Blood, 2013, 122, 4-4.	0.6	11

#	Article	IF	Citations
109	Treatment With Minihepcidin Peptide Improves Anemia and Iron Overload In a Mouse Model Of Thalassemia Intermedia. Blood, 2013, 122, 431-431.	0.6	9
110	Cellular Catabolism of the Iron-Regulatory Peptide Hormone Hepcidin. PLoS ONE, 2013, 8, e58934.	1.1	45
111	Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood, 2012, 120, 3829-3836.	0.6	184
112	Rethinking Iron Regulation and Assessment in Iron Deficiency, Anemia of Chronic Disease, and Obesity: Introducing Hepcidin. Journal of the Academy of Nutrition and Dietetics, 2012, 112, 391-400.	0.4	118
113	Hepcidin and iron homeostasis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 1434-1443.	1.9	947
114	Molecular Mechanism of Hepcidin-Mediated Ferroportin Internalization Requires Ferroportin Lysines, Not Tyrosines or JAK-STAT. Cell Metabolism, 2012, 15, 905-917.	7.2	124
115	Hepcidin-Induced Endocytosis of Ferroportin Is Dependent on Ferroportin Ubiquitination. Cell Metabolism, 2012, 15, 918-924.	7.2	261
116	IOD IN RHINOSâ€"IMMUNITY GROUP REPORT: REPORT FROM THE IMMUNITY, GENETICS AND TOXICOLOGY WORKING GROUP OF THE INTERNATIONAL WORKSHOP ON IRON OVERLOAD DISORDER IN BROWSING RHINOCEROS (FEBRUARY 2011). Journal of Zoo and Wildlife Medicine, 2012, 43, S117-S119.	0.3	4
117	Iron Metabolism: Interactions with Normal and Disordered Erythropoiesis. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a011668-a011668.	2.9	105
118	IRON HOMEOSTASIS AND ITS DISORDERS IN MICE AND MEN: POTENTIAL LESSONS FOR RHINOS. Journal of Zoo and Wildlife Medicine, 2012, 43, S19-S26.	0.3	13
119	Inhibition of hepcidin transcription by growth factors. Hepatology, 2012, 56, 291-299.	3.6	88
120	Hepcidin and Disorders of Iron Metabolism. Annual Review of Medicine, 2011, 62, 347-360.	5.0	404
121	The Hepcidin-Ferroportin System as a Therapeutic Target in Anemias and Iron Overload Disorders. Hematology American Society of Hematology Education Program, 2011, 2011, 538-542.	0.9	120
122	Subcutaneous Adipose Tissue from Obese and Lean Adults Does Not Release HepcidinIn Vivo. Scientific World Journal, The, 2011, 11, 2197-2206.	0.8	15
123	Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. Haematologica, 2011, 96, 1099-1105.	1.7	75
124	Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver International, 2011, 31, 994-1000.	1.9	24
125	Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology, 2011, 53, 1333-1341.	3.6	203
126	Intestinal ferroportin expression in pediatric CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2011, 17, 524-531.	0.9	10

#	Article	IF	Citations
127	Understanding the Structure/Activity Relationships of the Iron Regulatory Peptide Hepcidin. Chemistry and Biology, 2011, 18, 336-343.	6.2	50
128	A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica, 2011, 96, 500-506.	1.7	70
129	Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. Journal of Clinical Investigation, 2011, 121, 4880-4888.	3.9	198
130	THE METABOLIC FATE OF THE PEPTIDE HORMONE HEPCIDIN. FASEB Journal, 2011, 25, 1119.3.	0.2	0
131	Mini-Hepcidins Prevent Iron Overload In A Mouse Model of Hereditary Hemochromatosis. Blood, 2011, 118, 689-689.	0.6	0
132	Hepcidin in Male Double Red Blood Cell Donors - Relationship Between Parameters of Iron Metabolism and Erythropoiesis. Blood, 2011, 118, 2109-2109.	0.6	0
133	Proinflammatory state, hepcidin, and anemia in older persons. Blood, 2010, 115, 3810-3816.	0.6	191
134	In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood, 2010, 116, 3635-3644.	0.6	120
135	Decreased Serum Hepcidin and Improved Functional Iron Status 6 Months After Restrictive Bariatric Surgery. Obesity, 2010, 18, 2010-2016.	1.5	85
136	Hepcidin in Î²â€thalassemia. Annals of the New York Academy of Sciences, 2010, 1202, 31-35.	1.8	69
137	Hepcidin: an emerging biomarker for iron disorders, inflammatory diseases, and infections. Proceedings of SPIE, 2010, , .	0.8	1
138	Crosstalk between Erythropoiesis and Iron Metabolism. Advances in Hematology, 2010, 2010, 1-2.	0.6	6
139	Targeting the Hepcidin-Ferroportin Axis in the Diagnosis and Treatment of Anemias. Advances in Hematology, 2010, 2010, 1-9.	0.6	67
140	Î±1-Acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with Schistosoma haematobium. American Journal of Clinical Nutrition, 2010, 91, 1784-1790.	2.2	35
141	Reduction of Serum Hepcidin by Hemodialysis in Pediatric and Adult Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1010-1014.	2.2	86
142	Novel tools for the evaluation of iron metabolism. Haematologica, 2010, 95, 1989-1991.	1.7	5
143	Detection, evaluation, and management of iron-restricted erythropoiesis. Blood, 2010, 116, 4754-4761.	0.6	350
144	Elevated Systemic Hepcidin and Iron Depletion in Obese Premenopausal Females. Obesity, 2010, 18, 1449-1456.	1.5	131

#	Article	IF	Citations
145	Hepcidin as a therapeutic tool to limit iron overload and improve anemia in Î²-thalassemic mice. Journal of Clinical Investigation, 2010, 120, 4466-4477.	3.9	202
146	Excess Adiposity, Inflammation, and Iron-Deficiency in Female Adolescents. Journal of the American Dietetic Association, 2009, 109, 297-302.	1.3	93
147	Daily regulation of serum and urinary hepcidin is not influenced by submaximal cycling exercise in humans with normal iron metabolism. European Journal of Applied Physiology, 2009, 106, 435-443.	1.2	31
148	Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. Journal of Hepatology, 2009, 50, 1219-1225.	1.8	79
149	Reduced serum hepcidin levels in patients with chronic hepatitis C. Journal of Hepatology, 2009, 51, 845-852.	1.8	148
150	Hepcidinâ€"A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1051-1056.	2.2	279
151	The Role of Hepcidin in Iron Metabolism. Acta Haematologica, 2009, 122, 78-86.	0.7	477
152	Iron Sequestration and Anemia of Inflammation. Seminars in Hematology, 2009, 46, 387-393.	1.8	283
153	The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood, 2009, 114, 437-443.	0.6	149
154	Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation. Blood, 2009, 114, 493-494.	0.6	68
155	Development of Hepcidin Agonists and Antagonists.. Blood, 2009, 114, SCI-27-SCI-27.	0.6	1
156	The determinants of hepcidinâ€ferroportin interaction. FASEB Journal, 2009, 23, 974.4.	0.2	0
157	Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. British Journal of Haematology, 2008, 142, 669-671.	1.2	29
158	Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. Journal of Hepatology, 2008, 49, 123-133.	1.8	92
159	Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells, Molecules, and Diseases, 2008, 40, 122-131.	0.6	91
160	Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells, Molecules, and Diseases, 2008, 40, 347-352.	0.6	54
161	Involvement of Hepcidin in the Anemia of Multiple Myeloma. Clinical Cancer Research, 2008, 14, 3262-3267.	3.2	99
162	Immunoassay for human serum hepcidin. Blood, 2008, 112, 4292-4297.	0.6	605

#	Article	IF	Citations
163	Iron regulation and erythropoiesis. Current Opinion in Hematology, 2008, 15, 169-175.	1.2	152
164	Hepcidin Suppression Relative to Iron Status in Patients with Chronic Hepatitis C.. Blood, 2008, 112, 1860-1860.	0.6	0
165	The Molecular Mechanism of Hepcidin-mediated Ferroportin Down-Regulation. Molecular Biology of the Cell, 2007, 18, 2569-2578.	0.9	393
166	Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. Haematologica, 2007, 92, 1407-1410.	1.7	41
167	Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood, 2007, 110, 2182-2189.	0.6	235
168	Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood, 2007, 110, 4096-4100.	0.6	139
169	Liver iron concentrations and urinary hepcidin in Â-thalassemia. Haematologica, 2007, 92, 583-588.	1.7	339
170	Iron and aging. , 2007, , 171-180.		0
171	Urinary hepcidin in congenital chronic anemias. Pediatric Blood and Cancer, 2007, 48, 57-63.	0.8	157
172	Regulation of Iron Metabolism by Hepcidin. Annual Review of Nutrition, 2006, 26, 323-342.	4.3	653
173	The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood, 2006, 107, 328-333.	0.6	238
174	DMT1 mutation: response of anemia to darbepoetin administration and implications for iron homeostasis. Blood, 2006, 108, 404-405.	0.6	20
175	Impaired intestinal iron absorption in CrohnÊ¼s disease correlates with disease activity and markers of inflammation. Inflammatory Bowel Diseases, 2006, 12, 1101-1106.	0.9	148
176	Regulation of iron acquisition and iron distribution in mammals. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 690-699.	1.9	189
177	Iron imports. IV. Hepcidin and regulation of body iron metabolism. American Journal of Physiology - Renal Physiology, 2006, 290, G199-G203.	1.6	269
178	Molecular and clinical correlates in iron overload associated with mutations in ferroportin. Haematologica, 2006, 91, 1092-5.	1.7	43
179	Hepcidin and iron-loading anemias. Haematologica, 2006, 91, 727-32.	1.7	95
180	Hepcidin is decreased in TFR2 hemochromatosis. Blood, 2005, 105, 1803-1806.	0.6	368

#	Article	IF	Citations
181	Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood, 2005, 106, 746-748.	0.6	170
182	Ferroportin mutations: a tale of two phenotypes. Blood, 2005, 105, 3763-3764.	0.6	7
183	Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood, 2005, 106, 2196-2199.	0.6	274
184	Novel urine hepcidin assay by mass spectrometry. Blood, 2005, 106, 3268-3270.	0.6	125
185	Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood, 2005, 105, 1797-1802.	0.6	179
186	Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology, 2005, 42, 466-472.	3.6	54
187	Iron-regulatory protein hepcidin is increased in female athletes after a marathon. European Journal of Applied Physiology, 2005, 95, 569-571.	1.2	107
188	Hepcidin in iron overload disorders. Blood, 2005, 105, 4103-4105.	0.6	387
189	The molecular basis of ferroportin-linked hemochromatosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8955-8960.	3.3	210
190	Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood, 2005, 106, 1864-1866.	0.6	459
191	The N-Terminus of Hepcidin Is Essential for Its Interaction with Ferroportin: Structure-Function Study.. Blood, 2005, 106, 3588-3588.	0.6	0
192	Urinary Hepcidin in Thalassemic Syndromes.. Blood, 2005, 106, 3589-3589.	0.6	1
193	Mutations in HFE2 cause iron overload in chromosome 1qâ€“linked juvenile hemochromatosis. Nature Genetics, 2004, 36, 77-82.	9.4	900
194	Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science, 2004, 306, 2090-2093.	6.0	4,042
195	IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation, 2004, 113, 1271-1276.	3.9	1,809
196	IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation, 2004, 113, 1271-1276.	3.9	1,184
197	Hepcidin Contributes to Anemia of Malignancy by Causing Sequestration of Iron in Hepatic Stores.. Blood, 2004, 104, 3197-3197.	0.6	0
198	Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood, 2003, 101, 2461-2463.	0.6	1,245

#	Article	IF	Citations
199	Fetal membrane distention. American Journal of Obstetrics and Gynecology, 2000, 182, 50-59.	0.7	71
200	Fetal membrane distention. American Journal of Obstetrics and Gynecology, 2000, 182, 60-67.	0.7	65